Výsledky vyhľadávania - "Cytarabine: administration & dosage"

Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia

Autori: Chalandon, Yves Rousselot, Philippe Chevret, Sylvie a ďalší

Prispievatelia: Chalandon, Yves Rousselot, Philippe Chevret, Sylvie a ďalší

Zdroj: Blood, Vol. 143, no.23, p. 2363-2372 (2024)

Predmety: Male, Adult, Adolescent, Cytarabine / therapeutic use, Fusion Proteins, bcr-abl / genetics, Fusion Proteins, bcr-abl, Young Adult, Antineoplastic Combined Chemotherapy Protocols / therapeutic use, Antineoplastic Combined Chemotherapy Protocols / adverse effects, Pyrimidines / therapeutic use, Antineoplastic Combined Chemotherapy Protocols, Humans, Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy, Cytarabine, Hematopoietic Stem Cell Transplantation, Antineoplastic Combined Chemotherapy Protocols / administration & dosage, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Pyrimidines / administration & dosage, 3. Good health, Cytarabine / administration & dosage, Pyrimidines, Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy, Female, Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38452207
https://hdl.handle.net/2078.1/289800

Clinicopathologic conference: Bloodstream infection in an allogeneic hamatopoietic cell transplant: Thinking beyond the usual

Autori: Yeoh, Kim Lass-Flörl, Cornelia Lamoth, Frédéric a ďalší

Zdroj: Transplant infectious disease, vol. 26, no. 4, pp. e14273

Predmety: Hematopoietic Stem Cell Transplantation, Cytarabine, Humans, Middle Aged, Female, Leukemia, Myeloid, Acute/therapy, Leukemia, Myeloid, Acute/complications, Multiple Myeloma/therapy, Hematopoietic Stem Cell Transplantation/adverse effects, Transplantation, Homologous/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Cytarabine/therapeutic use, Cytarabine/administration & dosage, Induction Chemotherapy, bloodstream infection, hematopoietic stem cell transplant, immunocompromised, Bloodstream infection, 3. Good health, Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols, Transplantation, Homologous, Hematopoietic stem cell transplant, Multiple Myeloma, Immunocompromised

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38695847
https://archive-ouverte.unige.ch/unige:185596
https://doi.org/10.1111/tid.14273
https://serval.unil.ch/resource/serval:BIB_6497609B679D.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_6497609B679D1
https://serval.unil.ch/notice/serval:BIB_6497609B679D

MATRix–RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial: an international, single-arm, phase 2 trial

Autori: Ferreri A. J. M. Doorduijn J. K. Re A. a ďalší

Zdroj: Lancet Haematol
Ferreri, Andrés J M; Doorduijn, Jeanette K; Re, Alessandro; Cabras, Maria Giuseppina; Smith, Jeffery; Ilariucci, Fiorella; Luppi, Mario; Calimeri, Teresa; Cattaneo, Chiara; Khwaja, Jahanzaib; Botto, Barbara; Cellini, Claudia; Nassi, Luca; Linton, Kim; McKay, Pam; Olivieri, Jacopo; Patti, Caterina; Re, Francesca; Fanni, Alessandro; Singh, Vikram; ... (2021). MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. The Lancet. Haematology, 8(2), e110-e121. Elsevier 10.1016/S2352-3026(20)30366-5 <http://dx.doi.org/10.1016/S2352-3026(20)30366-5>
International Extranodal Lymphoma Study Group (IELSG) 2021, 'MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA) : an international, single-arm, phase 2 trial', The Lancet. Haematology, vol. 8, no. 2, pp. e110-e121. https://doi.org/10.1016/S2352-3026(20)30366-5

Predmety: Adult, Male, Autologous/adverse effects, Neutropenia, Lymphoma, Adolescent, EMC OR-01, Transplantation, Autologous/adverse effects, 610 Medicine & health, Kaplan-Meier Estimate, Central Nervous System Neoplasms/complications, Severity of Illness Index, Transplantation, Autologous, Disease-Free Survival, Rituximab/administration & dosage, Central Nervous System Neoplasms, Diffuse/complications, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Lymphoma, Large B-Cell, Diffuse/complications, SDG 3 - Good Health and Well-being, Antineoplastic Combined Chemotherapy Protocols, Large B-Cell, Humans, Hematopoietic Stem Cell Transplantation/adverse effects, Methotrexate/administration & dosage, Aged, Cytarabine/administration & dosage, Transplantation, Science & Technology, Neutropenia/etiology, Manchester Cancer Research Centre, Cytarabine, Hematopoietic Stem Cell Transplantation, Hematology, Articles, Middle Aged, ResearchInstitutes_Networks_Beacons/mcrc, name=Manchester Cancer Research Centre, 3. Good health, Methotrexate, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Lymphoma, Large B-Cell, Diffuse, Rituximab, Life Sciences & Biomedicine

Popis súboru: application/pdf; text

Prístupová URL adresa: http://www.thelancet.com/article/S2352302620303665/pdf
https://pubmed.ncbi.nlm.nih.gov/33513372
https://pure.eur.nl/en/publications/15268eb7-7541-4064-9969-358d4cf36a13
https://doi.org/10.1016/s2352-3026(20)30366-5
https://eprints.ncl.ac.uk/file_store/production/272933/11E3D218-18A8-439D-97F0-C0F74A8454F1.pdf
https://pubmed.ncbi.nlm.nih.gov/33513372/
https://www.sciencedirect.com/science/article/pii/S2352302620303665
https://iris.unimore.it/handle/11380/1250054
https://boris.unibe.ch/159168/
https://christie.openrepository.com/handle/10541/623780
https://boris.unibe.ch/159168/
https://discovery-pp.ucl.ac.uk/id/eprint/10156163/
https://eprints.soton.ac.uk/447286/

Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas

Autori: Jae-Cheol Jo Jin-Seok Kim Je-Hwan Lee a ďalší

Prispievatelia: Jae-Cheol Jo Jin-Seok Kim Je-Hwan Lee a ďalší

Zdroj: Annals of Hematology. 100:189-196

Predmety: Adult, Male, High-dose regimen, Transplantation Conditioning, Lymphoma, Antineoplastic Agents, Autologous stem cell transplantation, Transplantation, Autologous, Peripheral / diagnosis, Transplantation Conditioning / methods, Dose-Response Relationship, Hematopoietic Stem Cell Transplantation / methods, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Autologous / methods, Antineoplastic Combined Chemotherapy Protocols, Republic of Korea, Cytarabine / administration & dosage, Humans, Prospective Studies, T-cell lymphomas, Antineoplastic Combined Chemotherapy Protocols / administration & dosage, Antineoplastic Agents, Alkylating, Busulfan, Melphalan, Republic of Korea / epidemiology, Aged, Etoposide, Transplantation, Dose-Response Relationship, Drug, Phytogenic / administration & dosage, Cytarabine, Hematopoietic Stem Cell Transplantation, Lymphoma, T-Cell, Peripheral, Busulfan / administration & dosage, Middle Aged, T-Cell, Peripheral / drug therapy, Antineoplastic Agents, Phytogenic, Alkylating / administration & dosage, 3. Good health, Peripheral / epidemiology, Etoposide / administration & dosage, Female, Drug, Melphalan / administration & dosage

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/33205337
https://www.ncbi.nlm.nih.gov/pubmed/33205337
https://europepmc.org/article/MED/33205337
https://pubmed.ncbi.nlm.nih.gov/33205337/
https://snucm.elsevierpure.com/en/publications/busulfan-etoposide-cytarabine-and-melphalan-as-a-high-dose-regime
https://link.springer.com/article/10.1007/s00277-020-04309-7

Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long‐term follow up of a phase III study: long-term follow up of a phase III study

Autori: Baron, F. Efficace, F. Cannella, L. a ďalší

Prispievatelia: Baron, F. Efficace, F. Cannella, L. a ďalší

Zdroj: American Journal of Hematology, 95, 7, pp. 749-758

Predmety: Male, 0302 clinical medicine, Radboudumc 2: Cancer development and immune defence RIMLS: Radboud Institute for Molecular Life Sciences, Antineoplastic Combined Chemotherapy Protocols, inglese, Mitoxantrone / adverse effects, Human health sciences, Haematology - Radboud University Medical Center, Etoposide, Leukemia, Myeloid, Acute / therapy, Daunorubicin / administration & dosage, Age Factors, Cytarabine, Hematopoietic Stem Cell Transplantation, Idarubicin / adverse effects, Hematology, Induction Chemotherapy, Middle Aged, Allografts, 3. Good health, Leukemia, Myeloid, Acute, Cytarabine / administration & dosage, Female, Adult, Cytarabine / adverse effects, Adolescent, Idarubicin / administration & dosage, acute myeloid leukemia, anthracycline, Sciences de la santé humaine, Daunorubicin / adverse effects, Article, 03 medical and health sciences, Mitoxantrone / administration & dosage, Radboudumc 16: Vascular damage RIHS: Radboud Institute for Health Sciences, Humans, Etoposide / adverse effects, Antineoplastic Combined Chemotherapy Protocols / administration & dosage, HLA matching, Daunorubicin, Tumorimmunology - Radboud University Medical Center, HLA matching, anthracycline, acute myeloid leukemia, Leukemia, Myeloid, Acute / mortality, Etoposide / administration & dosage, Radboudumc 5: Inflammatory diseases RIHS: Radboud Institute for Health Sciences, Human Genetics - Radboud University Medical Center, Mitoxantrone, Idarubicin, Hématologie, Follow-Up Studies

Popis súboru: application/pdf

Prístupová URL adresa: https://orbi.uliege.be/bitstream/2268/250603/1/baron2020.pdf
https://pubmed.ncbi.nlm.nih.gov/32233095
https://www.bib.irb.hr/1274620
https://doi.org/10.1002/ajh.25795
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/220443
https://doi.org/10.1002/ajh.25795
https://orbi.uliege.be/handle/2268/250603
https://doi.org/10.1002/ajh.25795
https://www.narcis.nl/publication/RecordID/oai%3Arepository.ubn.ru.nl%3A2066%2F220443
https://doi.org/10.1002%2Fajh.25795
https://moh-it.pure.elsevier.com/en/publications/impact-of-the-type-of-anthracycline-and-of-stem-cell-transplantat
https://orbi.uliege.be/handle/2268/250603
https://onlinelibrary.wiley.com/doi/10.1002/ajh.25795
https://www.ncbi.nlm.nih.gov/pubmed/32233095
https://hdl.handle.net/1887/3185054
https://hdl.handle.net/2066/220443
https://repository.ubn.ru.nl//bitstream/handle/2066/220443/220443.pdf
https://hdl.handle.net/2268/250603
https://doi.org/10.1002/ajh.25795
https://urn.nsk.hr/urn:nbn:hr:105:157213
https://doi.org/10.1002/ajh.25795

Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival: methotrexate dose intensity correlates with response and survival

Autori: Nicolás Martinez‐Calle Edward Poynton Alia Alchawaf a ďalší

Zdroj: Martinez-Calle, N, Poynton, E, Alchawaf, A, Kassam, S, Horan, M, Rafferty, M, Kelsey, P, Scott, G, Culligan, D J, Buckley, H, Lim, Y J, Ngu, L, McCulloch, R, Rowntree, C, Wright, J, McKay, P, Fourali, S, Eyre, T A, Smith, J, Osborne, W, Yallop, D, Linton, K, Fox, C P & Cwynarski, K 2020, 'Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK : methotrexate dose intensity correlates with response and survival', British Journal of Haematology, vol. 190, no. 3, pp. 394-404. https://doi.org/10.1111/bjh.16592

Predmety: Adult, Male, Antimetabolites, Antineoplastic, Lymphoma, Antimetabolites, Antineoplastic/administration & dosage, Antimetabolites, Antineoplastic Agents, Kaplan-Meier Estimate, Antineoplastic Agents, Alkylating/administration & dosage, elderly, Rituximab/administration & dosage, Dose-Response Relationship, Central Nervous System Neoplasms, Lymphoma, Non-Hodgkin/drug therapy, 03 medical and health sciences, 0302 clinical medicine, Mthotrexate, Antineoplastic/administration & dosage, Antineoplastic Combined Chemotherapy Protocols, Humans, Methotrexate/administration & dosage, Antineoplastic Agents, Alkylating, PCNSL, Aged, Proportional Hazards Models, Retrospective Studies, Cytarabine/administration & dosage, Manchester Cancer Research Centre, Dose-Response Relationship, Drug, United Kingdom/epidemiology, Lymphoma, Non-Hodgkin, Remission Induction, real world, Cytarabine, ResearchInstitutes_Networks_Beacons/mcrc, name=Manchester Cancer Research Centre, Progression-Free Survival, 3. Good health, Consolidation Chemotherapy, Methotrexate, Wessex Classification Subject Headings::Haematology, DLBCL, Non-Hodgkin/drug therapy, high-dose therapy, Central Nervous System Neoplasms/drug therapy, Alkylating/administration & dosage, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Drug, Rituximab

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/32232989
https://research.manchester.ac.uk/en/publications/d15b8a10-cbe3-4b06-a8c1-6f0cfa89be31
https://doi.org/10.1111/bjh.16592
https://christie.openrepository.com/handle/10541/622904
https://eprints.ncl.ac.uk/265873
https://www.ncbi.nlm.nih.gov/pubmed/32232989
https://eprint.ncl.ac.uk/265873
https://onlinelibrary.wiley.com/doi/10.1111/bjh.16592
https://pubmed.ncbi.nlm.nih.gov/32232989/
https://research.manchester.ac.uk/en/publications/d15b8a10-cbe3-4b06-a8c1-6f0cfa89be31
http://www.scopus.com/inward/record.url?scp=85082613265&partnerID=8YFLogxK
https://doi.org/10.1111/bjh.16592

Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS

Autori: G. J. Ossenkoppele D. A. Breems G. Stuessi a ďalší

Prispievatelia: G. J. Ossenkoppele D. A. Breems G. Stuessi a ďalší

Zdroj: Ossenkoppele, G J, Breems, D A, Stuessi, G, van Norden, Y, Bargetzi, M, Biemond, B J, A von dem Borne, P, Chalandon, Y, Cloos, J, Deeren, D, Fehr, M, Gjertsen, B T, Graux, C, Huls, G, Janssen, J J J W, Jaspers, A, Jongen-Lavrencic, M, de Jongh, E, Klein, S K, Van der Klift, M, Van Marwijk Kooy, M, Maertens, J, Micheaux, L, van der Poel, M W M, Van Rhenen, A, Tick, L, Valk, P, Vekemans, M C, van der Velden, W J F M, de Weerdt, O, Pabst, T, Manz, M, Löwenberg, B & for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) 2020, 'Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS', Leukemia, vol. 34, no. 7, pp. 1751-1759. https://doi.org/10.1038/s41375-020-0725-0
Leukemia, 34, 7, pp. 1751-1759
Leukemia, Vol. 34, no. 7, p. 1751-1759 (2020)

Predmety: Male, 0301 basic medicine, HIGH-DOSE LENALIDOMIDE, ACUTE MYELOID-LEUKEMIA, Sciences de la santé humaine, THERAPY, 03 medical and health sciences, Leukemia, Myeloid, Acute / pathology, SDG 3 - Good Health and Well-being, Antineoplastic Combined Chemotherapy Protocols / therapeutic use, Myelodysplastic Syndromes / pathology, Antineoplastic Combined Chemotherapy Protocols, adults, Humans, Myelodysplastic Syndromes / drug therapy, Human health sciences, Lenalidomide, Haematology - Radboud University Medical Center, Aged, Aged, 80 and over, therapy, 0303 health sciences, high-dose lenalidomide, Lenalidomide / administration & dosage, Remission Induction, Cytarabine, Hematology, ADULTS, Induction Chemotherapy, Prognosis, 3. Good health, Survival Rate, Leukemia, Myeloid, Acute, Cytarabine / administration & dosage, Myelodysplastic Syndromes, Induction Chemotherapy / mortality, Radboudumc 5: Inflammatory diseases RIHS: Radboud Institute for Health Sciences, Female, acute myeloid-leukemia, Leukemia, Myeloid, Acute / drug therapy, Hématologie, Follow-Up Studies

Popis súboru: application/pdf

Prístupová URL adresa: https://pure.rug.nl/ws/files/118434471/Lenalidomide_added_to_standard_intensive_treatment_for_older_patients_with_AML_and_high_risk_MDS.pdf
https://pubmed.ncbi.nlm.nih.gov/32020044
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/225470
https://pure.eur.nl/en/publications/4b1aff2c-e2cb-405e-8a8b-55c872666769
https://doi.org/10.1038/s41375-020-0725-0
https://hdl.handle.net/11370/97f14b84-038f-45e9-8e79-0af373ddcd22
https://research.rug.nl/en/publications/97f14b84-038f-45e9-8e79-0af373ddcd22
https://doi.org/10.1038/s41375-020-0725-0
https://cris.maastrichtuniversity.nl/en/publications/cc27e680-8322-4302-aa67-107a6f3ccaa0
https://doi.org/10.1038/s41375-020-0725-0
https://www.nature.com/articles/s41375-020-0725-0.pdf
https://www.nature.com/articles/s41375-020-0725-0
https://research.rug.nl/en/publications/lenalidomide-added-to-standard-intensive-treatment-for-older-pati
https://www.rug.nl/research/portal/publications/lenalidomide-added-to-standard-intensive-treatment-for-older-patients-with-aml-and-highrisk-mds(97f14b84-038f-45e9-8e79-0af373ddcd22).html
https://pubmed.ncbi.nlm.nih.gov/32020044/
http://www.ncbi.nlm.nih.gov/pubmed/32020044
https://research.vumc.nl/en/publications/80af57dd-9848-40f6-b653-53245496ea78
https://pure.amsterdamumc.nl/en/publications/b2efe9ae-5634-47d6-bbb4-481825513e98
https://doi.org/10.1038/s41375-020-0725-0
https://hdl.handle.net/2066/225470
https://repository.ubn.ru.nl//bitstream/handle/2066/225470/225470.pdf
https://hdl.handle.net/2268/256384
https://doi.org/10.1038/s41375-020-0725-0
https://archive-ouverte.unige.ch/unige:182205
https://doi.org/10.1038/s41375-020-0725-0
https://hdl.handle.net/2078.1/230919

A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin’s lymphoma

Autori: Young-Woong Won Hyewon Lee Hyeon-Seok Eom a ďalší

Prispievatelia: Young-Woong Won Hyewon Lee Hyeon-Seok Eom a ďalší

Zdroj: Annals of Hematology. 99:255-264

Predmety: Adult, Male, Vascular Endothelial Growth Factor A, Cytarabine / adverse effects, Time Factors, Methylprednisolone, Disease-Free Survival, Oxaliplatin / administration & dosage, Hodgkin Disease* / mortality, 03 medical and health sciences, Tumor Necrosis Factor-alpha / blood, 0302 clinical medicine, Recurrence, Antineoplastic Combined Chemotherapy Protocols / adverse effects, Antineoplastic Combined Chemotherapy Protocols, Humans, Etoposide / adverse effects, Vascular Endothelial Growth Factor A / blood, Antineoplastic Combined Chemotherapy Protocols / administration & dosage, Oxaliplatin / adverse effects, Aged, Etoposide, Methylprednisolone / administration & dosage, Hodgkin's lymphoma, Methylprednisolone / adverse effects, Tumor Necrosis Factor-alpha, Hodgkin Disease* / blood, Cytarabine, Hodgkin Disease* / drug therapy, Middle Aged, Hodgkin Disease, Neoplasm Proteins / blood, Neoplasm Proteins, 3. Good health, Oxaliplatin, Survival Rate, C-Reactive Protein / metabolism, Cytarabine / administration & dosage, C-Reactive Protein, Etoposide / administration & dosage, Female

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/31897676
https://link.springer.com/article/10.1007/s00277-019-03891-9
https://pubmed.ncbi.nlm.nih.gov/31897676/
https://www.ncbi.nlm.nih.gov/pubmed/31897676
https://hanyang.elsevierpure.com/en/publications/a-phase-ii-study-of-etoposide-methylprednisolone-high-dose-cytara
https://snucm.elsevierpure.com/en/publications/a-phase-ii-study-of-etoposide-methylprednisolone-high-dose-cytara

Role of trabectedin in the treatment of soft tissue sarcoma.

Autori: Christinat, A. Leyvraz, S.

Predmety: Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Chromosomes, Human, Pair 14, Pair 4, Cytarabine/administration & dosage, Dexamethasone/administration & dosage, Disease-Free Survival, Female, Follow-Up Studies, Genetic Heterogeneity, Hemoglobins, Humans, Male, Middle Aged, Multiple Myeloma/drug therapy, Multiple Myeloma/genetics, Multivariate Analysis, Prognosis, Retrospective Studies, Translocation, Genetic, Vincristine/administration & dosage, beta 2-Microglobulin/blood

Popis súboru: application/pdf

Relation: OncoTargets and Therapy; https://iris.unil.ch/handle/iris/235258; serval:BIB_F99B330D2A0B; 000207823400001

Dostupnosť: https://iris.unil.ch/handle/iris/235258

Acute fatal myeloencephalopathy after combined intrathecal chemotherapy in a child with acute lymphoblastic leukemia

Autori: von der Weid, N. X. de Crousaz, H. Beck, D. a ďalší

Predmety: Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*adverse effects Brain Diseases/*chemically induced/pathology Child Coma/chemically induced Cytarabine/administration & dosage/adverse effects Female Humans Injections, Spinal Leukemia, Lymphocytic, Acute/*drug therapy Methotrexate/administration & dosage/adverse effects Neoplasm Recurrence, Local Paralysis/chemically induced Paraplegia/chemically induced Spinal Cord Diseases/*chemically induced/pathology

Relation: Medical and Pediatric Oncology; https://iris.unil.ch/handle/iris/223191; serval:BIB_CE72F5620F9D; A1991FJ87700008; 2023567

Dostupnosť: https://iris.unil.ch/handle/iris/223191
https://doi.org/10.1002/mpo.2950190309

Primary intracranial dural lymphoma of mucosa-associated lymphoid tissue (MALT) type: report of one case and review of the literature.

Autori: George, A.C. Ozsahin, M. Janzer, R. a ďalší

Predmety: Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Combined Modality Therapy, Cytarabine/administration & dosage, Dura Mater, Female, Humans, Hydrocortisone/administration & dosage, Lymphoma, B-Cell, Marginal Zone/cerebrospinal fluid, Marginal Zone/pathology, Meningeal Neoplasms/cerebrospinal fluid, Meningeal Neoplasms/pathology, Methotrexate/administration & dosage

Relation: Bulletin du Cancer; https://iris.unil.ch/handle/iris/155262; serval:BIB_D234D3407DDA

Dostupnosť: https://iris.unil.ch/handle/iris/155262

Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.

Autori: Löwenberg, B. van Putten, W. Theobald, M. a ďalší

Prispievatelia: Löwenberg, B. van Putten, W. Theobald, M. a ďalší

Predmety: Adult, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Cytarabine/administration & dosage, Disease-Free Survival, Female, Granulocyte Colony-Stimulating Factor/therapeutic use, Hematopoietic Stem Cell Mobilization, Humans, Idarubicin/administration & dosage, Leukemia, Myeloid, Acute/drug therapy, Acute/mortality, Male, Middle Aged, Recurrence, Remission Induction, Survival Analysis

Relation: New England Journal of Medicine; https://iris.unil.ch/handle/iris/115303; serval:BIB_28641; 000184843300004

Dostupnosť: https://iris.unil.ch/handle/iris/115303
https://doi.org/10.1056/NEJMoa025406

Intermediate-Dose Cytarabine as Postinduction AML Therapy

Autori: Hunault-Berger, Mathilde Pautas, Cécile Bertoli, Sarah a ďalší

Prispievatelia: Hunault-Berger, Mathilde Pautas, Cécile Bertoli, Sarah a ďalší

Zdroj: ISSN: 2766-5526 ; NEJM Evidence ; https://hal.science/hal-05162195 ; NEJM Evidence, 2025, 4 (7), pp.EVIDoa2400326. ⟨10.1056/evidoa2400326⟩.

Predmety: Cytarabine, Medicine, Oncology, Internal medicine, Chemotherapy, MESH: Adolescent, MESH: Adult, MESH: Humans, MESH: Leukemia, Myeloid, Acute* / drug therapy, Acute* / mortality, Acute* / therapy, MESH: Male, MESH: Middle Aged, MESH: Remission Induction, MESH: Treatment Outcome, MESH: Young Adult, MESH: Antimetabolites, Antineoplastic* / administration & dosage, Antineoplastic* / adverse effects, Antineoplastic* / therapeutic use, MESH: Cytarabine* / administration & dosage, MESH: Cytarabine* / adverse effects, MESH: Cytarabine* / therapeutic use, MESH: Female, MESH: Hematopoietic Stem Cell Transplantation, [SDV]Life Sciences [q-bio]

Relation: info:eu-repo/semantics/altIdentifier/pmid/40552969; PUBMED: 40552969

Dostupnosť: https://hal.science/hal-05162195
https://doi.org/10.1056/evidoa2400326

Liposomal Cytarabine Induces Less Neurocognitive Dysfunction Than Intrathecal Methotrexate in an Animal Model

Autori: Thomsen, Anna M Gulinello, Maria E Wen, Jing a ďalší

Zdroj: Journal of Pediatric Hematology/Oncology. 40:e91-e96

Predmety: Male, Cytarabine/administration & dosage, Antimetabolites, Antineoplastic, Antimetabolites, Animal, Cytarabine, Long-Evans, Delayed-Action Preparations/toxicity, Hematopoiesis, Rats, 3. Good health, Disease Models, Animal, 03 medical and health sciences, Cognition, 0302 clinical medicine, Antineoplastic/administration & dosage, Delayed-Action Preparations, Disease Models, Liposomes, Cognition/drug effects, Animals, Female, Rats, Long-Evans, Hematopoiesis/drug effects

Prístupová URL adresa: https://europepmc.org/articles/pmc5743776?pdf=render
https://pubmed.ncbi.nlm.nih.gov/28654460
https://www.ncbi.nlm.nih.gov/pubmed/28654460
https://www.researchwithrutgers.com/en/publications/liposomal-cytarabine-induces-less-neurocognitive-dysfunction-than
https://pubmed.ncbi.nlm.nih.gov/28654460/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743776
https://europepmc.org/articles/PMC5743776
https://einstein.pure.elsevier.com/en/publications/liposomal-cytarabine-induces-less-neurocognitive-dysfunction-than

Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes

Autori: Galtier, Jean Alric, Camille Bérard, Emilie a ďalší

Prispievatelia: Galtier, Jean Alric, Camille Bérard, Emilie a ďalší

Zdroj: ISSN: 2044-5385 ; Blood Cancer Journal ; https://ut3-toulouseinp.hal.science/hal-04501344 ; Blood Cancer Journal, 2021, 11, pp.180. ⟨10.1038/s41408-021-00551-y⟩.

Predmety: MESH: Aged, MESH: Anthracyclines / administration & dosage, MESH: Remission Induction, MESH: Antineoplastic Combined Chemotherapy Protocols / administration & dosage, MESH: Cytarabine / administration & dosage, MESH: Female, MESH: Humans, MESH: Leukemia, Myeloid, Acute / drug therapy, MESH: Male, MESH: Middle Aged, MESH: Registries, [SDV.CAN]Life Sciences [q-bio]/Cancer

Relation: info:eu-repo/semantics/altIdentifier/pmid/34775463; PUBMED: 34775463; PUBMEDCENTRAL: PMC8590686

Dostupnosť: https://ut3-toulouseinp.hal.science/hal-04501344
https://ut3-toulouseinp.hal.science/hal-04501344v1/document
https://ut3-toulouseinp.hal.science/hal-04501344v1/file/Galtier_2021.pdf
https://doi.org/10.1038/s41408-021-00551-y

Efficacy of CLARA in recurrent/refractory acute myeloid leukaemia patients unresponsive to FLAG chemotherapy

Autori: Kaya AH Tekgündüz E Ilkkiliç K a ďalší

Zdroj: Journal of Chemotherapy. 30:44-48

Predmety: Male, CD135 antigen, drug safety, typhlitis, myeloablative agent, retrospective study, drug response, rash, genetic risk, cytogenetics, granulocyte colony stimulating factor, sepsis, analogs and derivatives, 0302 clinical medicine, AML, cytarabine, middle aged, Antineoplastic Combined Chemotherapy Protocols, Granulocyte Colony-Stimulating Factor, Relapse, busulfan, salvage therapy, antineoplastic agent, arabinonucleoside, clinical article, Adenine Nucleotides, granulocyte colony stimulating factor receptor, adult, nephrotoxicity, drug effect, Cytarabine, clinical trial, Adenine Nucleotides/*administration & dosage/adverse effects, Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Arabinonucleosides/*administration & dosage/adverse effects, Clofarabine, Cytarabine/*administration & dosage/adverse effects, Drug Resistance, Neoplasm/drug effects, Female, Humans, Leukemia, Myeloid, Acute/*drug therapy, Middle Aged, Neoplasm Recurrence, Local/*drug therapy, Retrospective Studies, Sa, liver toxicity, 3. Good health, aged, Leukemia, Myeloid, Acute, female, nephroblastoma, young adult, nucleophosmin, adenine nucleotide, Vidarabine, vidarabine, survival rate, overall survival, acute myeloid leukemia, Acute myeloid leukaemia, methotrexate, Article, Young Adult, 03 medical and health sciences, reduced intensity conditioning, male, follow up, neutropenia, cyclosporine, allogeneic hematopoietic stem cell transplantation, human, procedures, Salvage Therapy, drug resistance, Refractory, graft versus host reaction, fludarabine, tumor recurrence, drug efficacy, febrile neutropenia, multicenter study, clofarabine, Drug Resistance, Neoplasm, adolescent, cyclophosphamide, observational study, Arabinonucleosides, Neoplasm Recurrence, Local

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/29098953
https://pubmed.ncbi.nlm.nih.gov/29098953/
https://www.tandfonline.com/doi/full/10.1080/1120009X.2017.1396017
http://europepmc.org/abstract/MED/29098953
https://www.ncbi.nlm.nih.gov/pubmed/29098953
https://hdl.handle.net/11499/10870
https://doi.org/10.1080/1120009x.2017.1396017

Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial

Autori: Agnieszka Pluta Tadeusz Robak Agata Wrzesien‐Kus a ďalší

Zdroj: American Journal of Hematology. 92:359-366

Predmety: Male, Cladribine - administration & dosage, acute - mortality, acute - genetics, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Daunorubicin - administration & dosage, Humans, Middle aged, Aged, Leukemia, Cladribine - pharmacology, Cytarabine - administration & dosage, Daunorubicin, Remission Induction, Age Factors, Cytarabine, Induction Chemotherapy, Middle Aged, 3. Good health, Leukemia, Myeloid, Acute, Antineoplastic combined chemotherapy protocols - therapeutic use, Remission induction, Karyotyping, Cladribine, acute - drug therapy, Female, Induction chemotherapy - methods, Poland, myeloid, Age factors

Prístupová URL adresa: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.24654
https://pubmed.ncbi.nlm.nih.gov/28103640
https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.24654
https://europepmc.org/article/MED/28103640
https://pubmed.ncbi.nlm.nih.gov/28103640/
https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.24654
https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.24654
https://doi.org/10.1002/ajh.24654

Liposomal cytarabine as cancer therapy: From chemistry to medicine

Autori: Salehi, B Selamoglu, Z Mileski, KS a ďalší

Prispievatelia: Salehi, B Selamoglu, Z Mileski, KS a ďalší

Predmety: Animals, Antineoplastic Agents / administration & dosage, Antineoplastic Agents / chemistry, Cytarabine / administration & dosage, Cytarabine / chemistry, Drug Compounding, Humans, Liposomes / chemistry, Neoplasms / drug therapy

Popis súboru: application/pdf

Relation: info:eu-repo/grantAgreement/FCT/5876/147342/PT; Biomolecules, vol.9(12):773; https://www.mdpi.com/2218-273X/9/12/773; https://hdl.handle.net/10216/138971

Dostupnosť: https://hdl.handle.net/10216/138971
https://doi.org/10.3390/biom9120773

A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients: Results from the UK NCRI AML17 trial in 1206 patients

Autori: Burnett, Alan K Russell, Nigel H Hills, Robert K a ďalší

Zdroj: The UK NCRI AML Study Group 2015, ' A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction : Results from the UK NCRI AML17 trial in 1206 patients ', Blood, vol. 125, no. 25, pp. 3878-3885 . https://doi.org/10.1182/blood-2015-01-623447

Predmety: Myeloid, Adult, Male, Adolescent, Leukemia, Myeloid, Acute/drug therapy, Kaplan-Meier Estimate, Dose-Response Relationship, Induction Chemotherapy/methods, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Antibiotics, Antineoplastic/administration & dosage, Antineoplastic Combined Chemotherapy Protocols, Acute/drug therapy, Humans, Aged, Cytarabine/administration & dosage, Leukemia, Antibiotics, Antineoplastic, Dose-Response Relationship, Drug, Daunorubicin, Cytarabine, Induction Chemotherapy, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Middle Aged, 3. Good health, Leukemia, Myeloid, Acute, Antibiotics, Antineoplastic/administration & dosage, Female, Drug, Daunorubicin/administration & dosage

Prístupová URL adresa: https://ashpublications.org/blood/article-pdf/125/25/3878/1386821/3878.pdf
https://pubmed.ncbi.nlm.nih.gov/25833957
https://ashpublications.org/blood/article/125/25/3878/34316/A-randomized-comparison-of-daunorubicin-90-mg-m2
https://www.sciencedirect.com/science/article/pii/S0006497120315263
https://pure.qub.ac.uk/portal/en/publications/a-randomised-comparison-of-daunorubicin-90mgm2-vs-60mgm2-in-aml-induction-results-from-the-uk-ncri-aml17-trial-in-1206-patients(443b6809-6ea4-42a4-88d5-f049b1d60a68).html
https://pubmed.ncbi.nlm.nih.gov/25833957/
http://europepmc.org/articles/PMC4505010
https://www.ctsu.ox.ac.uk/publications/930145
https://portal.findresearcher.sdu.dk/da/publications/823c2601-ae67-467f-b324-54a36712ae98

Response‐guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML‐01: Results from protocol DB AML-01

Autori: Barbara De Moerloose Ardine Reedijk Geertruida H de Bock a ďalší

Prispievatelia: Barbara De Moerloose Ardine Reedijk Geertruida H de Bock a ďalší

Zdroj: de Moerloose, B, Reedijk, A, de Bock, G H, Lammens, T, de Haas, V, Denys, B, Dedeken, L, van den Heuvel-Eibrink, M M, te Loo, M, Uyttebroeck, A, van Damme, A, van der Werff-ten Bosch, J, Zsiros, J, Kaspers, G & de Bont, E 2019, 'Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML-01', Pediatric Blood and Cancer, vol. 66, no. 5, e27605. https://doi.org/10.1002/pbc.27605
Pediatric Blood & Cancer, 66, 5

Predmety: Male, Child, preschool, Adolescent, DB AML-01, Leukemia, Myeloid, Acute/drug therapy, MULTICENTER, Radboud University Medical Center, CHILDREN, anthracycline, Anthracyclines/administration & dosage, THERAPY, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Anthracyclines, Prospective Studies, Child, pediatric AML, RISK, Cytarabine/administration & dosage, INDUCTION, Remission Induction, Cytarabine, Infant, Newborn, Infant, Radboudumc 9: Rare cancers RIHS: Radboud Institute for Health Sciences, EMC MM-02-54-03, Prognosis, INTERNAL TANDEM DUPLICATION, RANDOMIZED-TRIAL, CYTARABINE, 3. Good health, Survival Rate, SORAFENIB, Leukemia, Myeloid, Acute, Child, Preschool, HSCT, outcome, SURVIVAL, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Nucleophosmin, Follow-Up Studies

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/30623572
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/202443
https://doi.org/10.1002/pbc.27605
https://research.rug.nl/en/publications/657d9a31-ba98-4d7c-a21f-33b3adc08771
https://hdl.handle.net/11370/657d9a31-ba98-4d7c-a21f-33b3adc08771
https://doi.org/10.1002/pbc.27605
https://researchportal.vub.be/en/publications/response-guided-chemotherapy-for-pediatric-acute-myeloid-leukemia
https://europepmc.org/abstract/MED/30623572
https://research.rug.nl/en/publications/response-guided-chemotherapy-for-pediatric-acute-myeloid-leukemia
https://www.ncbi.nlm.nih.gov/pubmed/30623572
https://repub.eur.nl/pub/116348
https://research.vumc.nl/en/publications/response-guided-chemotherapy-for-pediatric-acute-myeloid-leukemia
https://research.vumc.nl/en/publications/835af0a2-2611-4b83-945d-cbe51536d7df
https://pure.amsterdamumc.nl/en/publications/a3601a15-b120-447d-9762-59fd394a12f3
https://doi.org/10.1002/pbc.27605
https://hdl.handle.net/2066/202443
https://repository.ubn.ru.nl//bitstream/handle/2066/202443/202443.pdf
https://biblio.vub.ac.be/vubir/(ca6c23bd-2914-40c8-98ca-5387b806c622).html